Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Vitolo

Showing results (151-160 of 212) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
American Journal of Hematology|October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsNicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell LymphomaUmberto Vitolo, Marek Trněný, David Belada, et al.
British Journal of Haematology|November 28, 2008
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trialBarry W Hancock, Wendi Qian, David Linch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Bone Marrow Transplantation|July 8, 2021
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long termSergio Cortelazzo, Michael Mian, Andrea Evangelista, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Pageof 22

Showing results (151-160 of 212) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
American Journal of Hematology|October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsNicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell LymphomaUmberto Vitolo, Marek Trněný, David Belada, et al.
British Journal of Haematology|November 28, 2008
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trialBarry W Hancock, Wendi Qian, David Linch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Bone Marrow Transplantation|July 8, 2021
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long termSergio Cortelazzo, Michael Mian, Andrea Evangelista, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Pageof 22